Literature DB >> 11784783

Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.

Jose A Morón1, Alicia Brockington, Roy A Wise, Beatriz A Rocha, Bruce T Hope.   

Abstract

Selective blockers of the norepinephrine transporter (NET) inhibit dopamine uptake in the prefrontal cortex. This suggests that dopamine in this region is normally cleared by the somewhat promiscuous NET. We have tested this hypothesis by comparing the effects of inhibitors selective for the three monoamine transporters with those of a nonspecific inhibitor, cocaine, on uptake of 3H-dopamine into synaptosomes from frontal cortex, caudate nucleus, and nucleus accumbens from wild-type, NET, and dopamine transporter (DAT) knock-out mice. Dopamine uptake was inhibited by cocaine and nisoxetine, but not by GBR12909, in frontal cortex synaptosomes from wild-type or DAT knock-out mice. At transporter-specific concentrations, nisoxetine and GBR12909 failed to block dopamine uptake into frontal cortex synaptosomes from NET knock-out mice. The efficacy of cocaine at the highest dose (1 mm) was normal in DAT knock-out mice but reduced by 70% in NET knock-out mice. Nisoxetine inhibited dopamine uptake by 20% in caudate and nucleus accumbens synaptosomes from wild-type and DAT knock-out mice but had no effect in those from NET knock-out mice. Cocaine failed to block dopamine uptake into caudate or nucleus accumbens synaptosomes from DAT knock-out mice. Cocaine and GBR12909 each inhibited dopamine uptake into caudate synaptosomes from NET knock-out mice, but cocaine effectiveness was reduced in the case of nucleus accumbens synaptosomes. Thus, whereas dopamine uptake in caudate and nucleus accumbens depends primarily on the DAT, dopamine uptake in frontal cortex depends primarily on the NET. These data underscore the fact that which transporter clears dopamine from a given region depends on both the affinities and the local densities of the transporters.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11784783      PMCID: PMC6758674     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

Review 1.  Brain noradrenaline and the mechanisms of action of antidepressant drugs.

Authors:  T H Svensson
Journal:  Acta Psychiatr Scand Suppl       Date:  2000

2.  Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.

Authors:  I Sora; F S Hall; A M Andrews; M Itokawa; X F Li; H B Wei; C Wichems; K P Lesch; D L Murphy; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  Habit-forming actions of nomifensine in nucleus accumbens.

Authors:  W A Carlezon; D P Devine; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

4.  Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals.

Authors:  E Carboni; G L Tanda; R Frau; G Di Chiara
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

5.  In vivo assessment of dopamine uptake in rat medial prefrontal cortex: comparison with dorsal striatum and nucleus accumbens.

Authors:  W A Cass; G A Gerhardt
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

6.  Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine.

Authors:  H De Wit; R A Wise
Journal:  Can J Psychol       Date:  1977-12

7.  Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine.

Authors:  M Raiteri; R Del Carmine; A Bertollini; G Levi
Journal:  Eur J Pharmacol       Date:  1977-01-21       Impact factor: 4.432

8.  Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.

Authors:  X Wu; R Kekuda; W Huang; Y J Fei; F H Leibach; J Chen; S J Conway; V Ganapathy
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

9.  Regulation of extracellular dopamine by the norepinephrine transporter.

Authors:  B K Yamamoto; S Novotney
Journal:  J Neurochem       Date:  1998-07       Impact factor: 5.372

10.  Transport of monoamine transmitters by the organic cation transporter type 2, OCT2.

Authors:  D Gründemann; S Köster; N Kiefer; T Breidert; M Engelhardt; F Spitzenberger; N Obermüller; E Schömig
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

View more
  208 in total

1.  In vivo voltammetric monitoring of catecholamine release in subterritories of the nucleus accumbens shell.

Authors:  J Park; B J Aragona; B M Kile; R M Carelli; R M Wightman
Journal:  Neuroscience       Date:  2010-05-06       Impact factor: 3.590

2.  Differentiating the rapid actions of cocaine.

Authors:  Roy A Wise; Eugene A Kiyatkin
Journal:  Nat Rev Neurosci       Date:  2011-06-02       Impact factor: 34.870

3.  Hippocampal GluA1-containing AMPA receptors mediate context-dependent sensitization to morphine.

Authors:  Yan Xia; George S Portugal; Amanda K Fakira; Zara Melyan; Rachael Neve; H Thomas Lee; Scott J Russo; Jie Liu; Jose A Morón
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

4.  Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Authors:  Piotr Popik; Martyna Krawczyk; Krystyna Golembiowska; Gabriel Nowak; Aaron Janowsky; Phil Skolnick; Arnold Lippa; Anthony S Basile
Journal:  Cell Mol Neurobiol       Date:  2006-04-25       Impact factor: 5.046

5.  Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder.

Authors:  Nora D Volkow; Gene-Jack Wang; Dardo Tomasi; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank W Telang; Joanna S Fowler; Jean Logan; Christopher T Wong; James M Swanson
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

6.  Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Authors:  Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

7.  DAT1 and COMT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls.

Authors:  Yannis Paloyelis; Philip Asherson; Mitul A Mehta; Stephen V Faraone; Jonna Kuntsi
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

8.  Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults.

Authors:  W Retz; M Rösler; C Kissling; S Wiemann; R Hünnerkopf; A Coogan; J Thome; C Freitag
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

Review 9.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.